Suggested remit: To appraise the clinical and cost effectiveness of low-dose atropine eye drops within its marketing authorisation for treating myopia in people 3 to 14 years.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information Scoping commenced.
Process STA Standard
ID number 6517

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 June 2025 The NICE Prioritisation Board (PB) met on Monday 16 June 2025 to consider the findings of the scoping exercise for this topic. PB subsequently agreed that low-dose atropine eye drops for treating myopia in people 3 to 14 years, should be selected for evaluation and ministerial referral from the Department of Health and Social Care (DHSC) will now be sought
24 March 2025 - 23 April 2025 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: ID6517
24 March 2025 In progress
12 December 2024 Awaiting development
12 December 2024 Topic selection. .

For further information on our processes and methods, please see our CHTE processes and methods manual